Latest Health Care News

PainChek appoints seasoned US medtech executive Karen Holzberger as CEO to spearhead growth following FDA clearance and major US contracts.

PainChek announces the immediate departure of CEO Philip Daffas, with COO Andy Hoggan stepping in as interim leader amid a strategic pivot to boost US market growth following FDA clearance.

Healius has secured a national pathology services agreement with Ramsay Health Care subsidiaries, consolidating its role across 13 hospitals and stabilising a key revenue stream worth around $45 million annually.

Marlin Global’s portfolio lagged the broader market in May 2026, weighed down by semiconductor underexposure and near-term revenue challenges in key holdings, while AI-focused stocks powered a narrow rally.

HealthCo Healthcare & Wellness REIT has reached a government-backed agreement with Bethesda Health Care to operate the Mount Private Hospital, marking a significant step in resolving Healthscope-related uncertainties and ensuring long-term portfolio stability.

PainChek has secured A$5.5 million via convertible notes to accelerate its US sales expansion and strengthen working capital amid key commercial milestones.

Kingfish Limited’s portfolio edged higher in April, buoyed by strong performances from Mercury and Infratil, while a2 Milk and Summerset weighed on returns amid operational and economic headwinds.

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.

Nutritional Growth Solutions (ASX: NGS) has completed a major operational reset, achieving normalised profitability, eliminating all debt, and replenishing inventory to support renewed growth.

Ramsay Health Care has announced a fully franked distribution of AUD 3.3608 per security on its perpetual preference shares, subject to board approval by late August. The payment reflects a total annualised rate of 6.7%, linked to the 180-day BBSW plus a margin.

PainChek has secured a landmark agreement with Sabra Health Care REIT to deploy its AI-powered pain assessment across up to 20,000 beds in North America, marking a pivotal step in its US expansion.

Cyclopharm Limited is rapidly expanding its Technegas® lung imaging technology across the US, securing new contracts and advancing clinical guideline recognition that could boost adoption.